Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.80 |
| ▸ | CDK1 | P06493 | 17/20 | 0.80 |
| ▸ | CCNE1 | P24864 | 17/20 | 0.80 |
| ▸ | FLT3 | P36888 | 4/20 | 0.80 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.80 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.80 |
| ▸ | CDK4 | P11802 | 3/20 | 0.80 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.80 |
| ▸ | CCND1 | P24385 | 3/20 | 0.80 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.80 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.78 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.78 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.73 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.67 |
| ▸ | CDK7 | P50613 | 1/20 | 0.67 |
| ▸ | CDK9 | P50750 | 1/20 | 0.67 |
| ▸ | CCNH | P51946 | 1/20 | 0.67 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.67 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.67 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5193267 | 1.00 | CDK2 (0.80) | CDK2CDK1CCNE1FLT3CCNE2 | |
| SCHEMBL15941042 | 0.97 | CDK2 (0.83) | CDK2CDK1CCNE1FLT3CCNE2 | |
| SCHEMBL5194304 | 0.93 | CDK2 (0.71) | CDK2CDK1CCNE1FLT3CCNE2 | |
| SCHEMBL15940702 | 0.91 | CDK2 (0.83) | CDK2CDK1CCNE1FLT3CCNE2 | |
| SCHEMBL5196111 | 0.90 | CDK2 (0.78) | CDK2CDK1CCNE1FLT3CCNE2 | |
| SCHEMBL5196126 | 0.90 | CDK2 (0.78) | CDK2CDK1CCNE1FLT3CCNE2 | |
| SCHEMBL15940978 | 0.90 | CDK2 (0.71) | CDK2CDK1CCNE1FLT3CCNE2 | |
| SCHEMBL4314535 | 0.89 | CDK2 (1.00) | CDK2CDK1CCNE1FLT3CCNE2 | |
| SCHEMBL4314539 | 0.89 | CDK2 (1.00) | CDK2CDK1CCNE1FLT3CCNE2 | |
| SCHEMBL17352625 | 0.89 | CDK2 (0.69) | CDK2CDK1CCNE1FLT3CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183256-B1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2007-08-22 | — | — | EP | claimed |
| JP-2003500407-A | — | — | 2003-01-07 | — | — | JP | claimed |
| EP-1183256-A1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2002-03-06 | — | — | EP | claimed |
| WO-2000071543-A1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2000-11-30 | — | — | WO | claimed |
| EP-1183256-B1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2007-08-22 | — | — | EP | disclosed |
| US-7208598-B2 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA (FR) | 2007-04-24 | — | — | US | disclosed |
| US-7122669-B1 | Purine derivatives, preparation method and pharmaceutical compositions containing same | HOECHST MARION ROUSSEL (FR) | 2006-10-17 | — | — | US | disclosed |
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2005-08-25 | — | — | US | disclosed |
| EP-1183256-A1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071543-A1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | CDK6, CDK1, CDK2 | CDK2 3/4885CDK1 2/4885CCNE1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.